Literature DB >> 25964474

Allergic Lung Inflammation Reduces Tissue Invasion and Enhances Survival from Pulmonary Pneumococcal Infection in Mice, Which Correlates with Increased Expression of Transforming Growth Factor β1 and SiglecF(low) Alveolar Macrophages.

Alan M Sanfilippo1, Yoichi Furuya1, Sean Roberts1, Sharon L Salmon1, Dennis W Metzger2.   

Abstract

Asthma is generally thought to confer an increased risk for invasive pneumococcal disease (IPD) in humans. However, recent reports suggest that mortality rates from IPD are unaffected in patients with asthma and that chronic obstructive pulmonary disease (COPD), a condition similar to asthma, protects against the development of complicated pneumonia. To clarify the effects of asthma on the subsequent susceptibility to pneumococcal infection, ovalbumin (OVA)-induced allergic lung inflammation (ALI) was induced in mice followed by intranasal infection with A66.1 serotype 3 Streptococcus pneumoniae. Surprisingly, mice with ALI were significantly more resistant to lethal infection than non-ALI mice. The heightened resistance observed following ALI correlated with enhanced early clearance of pneumococci from the lung, decreased bacterial invasion from the airway into the lung tissue, a blunted inflammatory cytokine and neutrophil response to infection, and enhanced expression of transforming growth factor β1 (TGF-β1). Neutrophil depletion prior to infection had no effect on enhanced early bacterial clearance or resistance to IPD in mice with ALI. Although eosinophils recruited into the lung during ALI appeared to be capable of phagocytizing bacteria, neutralization of interleukin-5 (IL-5) to inhibit eosinophil recruitment likewise had no effect on early clearance or survival following infection. However, enhanced resistance was associated with an increase in levels of clodronate-sensitive, phagocytic SiglecF(low) alveolar macrophages within the airways following ALI. These findings suggest that, while the risk of developing IPD may actually be decreased in patients with acute asthma, additional clinical data are needed to better understand the risk of IPD in patients with different asthma phenotypes.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964474      PMCID: PMC4468552          DOI: 10.1128/IAI.00142-15

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  Pathogenesis, treatment, and prevention of pneumococcal pneumonia.

Authors:  Tom van der Poll; Steven M Opal
Journal:  Lancet       Date:  2009-10-31       Impact factor: 79.321

2.  Severity and outcomes of community acquired pneumonia in asthmatic patients.

Authors:  Silvia Terraneo; Eva Polverino; Catia Cilloniz; Rosanel Amaro; M del Carmen Vennera; Albert Gabarrus; Beatriz Montull; Encarnación Moreno; Rosario Menendez; Stefano Centanni; Antoni Torres
Journal:  Respir Med       Date:  2014-09-16       Impact factor: 3.415

3.  Interleukin-12 promotes gamma interferon-dependent neutrophil recruitment in the lung and improves protection against respiratory Streptococcus pneumoniae infection.

Authors:  Keer Sun; Sharon L Salmon; Steven A Lotz; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-01-08       Impact factor: 3.441

4.  Asthma as a risk factor for invasive pneumococcal disease.

Authors:  Thomas R Talbot; Tina V Hartert; Ed Mitchel; Natasha B Halasa; Patrick G Arbogast; Katherine A Poehling; William Schaffner; Allen S Craig; Marie R Griffin
Journal:  N Engl J Med       Date:  2005-05-19       Impact factor: 91.245

5.  Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes.

Authors:  C Cillóniz; S Ewig; E Polverino; C Muñoz-Almagro; F Marco; A Gabarrús; R Menéndez; J Mensa; A Torres
Journal:  Clin Microbiol Infect       Date:  2011-11-01       Impact factor: 8.067

6.  Influence of neutropenia on the course of serotype 8 pneumococcal pneumonia in mice.

Authors:  Matthew Marks; Tamika Burns; Maria Abadi; Beza Seyoum; Justin Thornton; Elaine Tuomanen; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

7.  Increased risk of serious pneumococcal disease in patients with asthma.

Authors:  Young J Juhn; Hirohito Kita; Barbara P Yawn; Thomas G Boyce; Kwang H Yoo; Michaela E McGree; Amy L Weaver; Peter Wollan; Robert M Jacobson
Journal:  J Allergy Clin Immunol       Date:  2008-09-13       Impact factor: 10.793

8.  Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma.

Authors:  Anne M Fitzpatrick; Fernando Holguin; W Gerald Teague; Lou Ann S Brown
Journal:  J Allergy Clin Immunol       Date:  2008-04-16       Impact factor: 10.793

9.  Invasive pneumococcal disease in patients with an underlying pulmonary disorder.

Authors:  M Inghammar; G Engström; G Kahlmeter; B Ljungberg; C-G Löfdahl; A Egesten
Journal:  Clin Microbiol Infect       Date:  2013-03-07       Impact factor: 8.067

10.  Selective stimulation of IL-4 receptor on smooth muscle induces airway hyperresponsiveness in mice.

Authors:  Charles Perkins; Noriko Yanase; George Smulian; Lucy Gildea; Tatyana Orekov; Crystal Potter; Frank Brombacher; Bruce Aronow; Marsha Wills-Karp; Fred D Finkelman
Journal:  J Exp Med       Date:  2011-04-04       Impact factor: 14.307

View more
  9 in total

1.  A Triple-challenge Mouse Model of Allergic Airway Disease, Primary Influenza Infection, and Secondary Bacterial Infection.

Authors:  Sean Roberts; Clare M Williams; Sreeja Roy; Yoichi Furuya
Journal:  Bio Protoc       Date:  2020-04-20

2.  Peptidoglycan Recognition Protein 3 Does Not Alter the Outcome of Pneumococcal Pneumonia in Mice.

Authors:  Anshu Shrivastav; Alexander N Dabrowski; Claudia Conrad; Nelli Baal; Holger Hackstein; Stephanie Plog; Kristina Dietert; Achim D Gruber; Philippe D N'Guessan; Sahar Aly; Norbert Suttorp; Janine Zahlten
Journal:  Front Microbiol       Date:  2018-02-01       Impact factor: 5.640

3.  Allergic Airway Disease Prevents Lethal Synergy of Influenza A Virus-Streptococcus pneumoniae Coinfection.

Authors:  Sean Roberts; Sharon L Salmon; Donald J Steiner; Clare M Williams; Dennis W Metzger; Yoichi Furuya
Journal:  mBio       Date:  2019-07-02       Impact factor: 7.867

Review 4.  Apoptosis of Eosinophil Granulocytes.

Authors:  Martina Zustakova; Lucie Kratochvilova; Petr Slama
Journal:  Biology (Basel)       Date:  2020-12-10

5.  Can Eosinophils Prevent Lung Injury? Ask PHIL.

Authors:  Christopher M Evans; Alexandra L McCubbrey
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

6.  IL-33-mediated Eosinophilia Protects against Acute Lung Injury.

Authors:  Paulette A Krishack; Maile K Hollinger; Timothy G Kuzel; Trevor S Decker; Tyler J Louviere; Cara L Hrusch; Anne I Sperling; Philip A Verhoef
Journal:  Am J Respir Cell Mol Biol       Date:  2021-05       Impact factor: 6.914

Review 7.  Impact of Therapeutics on Unified Immunity During Allergic Asthma and Respiratory Infections.

Authors:  Armando S Flores-Torres; Amali E Samarasinghe
Journal:  Front Allergy       Date:  2022-03-25

8.  Allergic Asthma Favors Brucella Growth in the Lungs of Infected Mice.

Authors:  Arnaud Machelart; Georges Potemberg; Laurye Van Maele; Aurore Demars; Maxime Lagneaux; Carl De Trez; Catherine Sabatel; Fabrice Bureau; Sofie De Prins; Pauline Percier; Olivier Denis; Fabienne Jurion; Marta Romano; Jean-Marie Vanderwinden; Jean-Jacques Letesson; Eric Muraille
Journal:  Front Immunol       Date:  2018-08-10       Impact factor: 7.561

9.  House Dust Mite Aeroallergen Suppresses Leukocyte Phagocytosis and Netosis Initiated by Pneumococcal Lung Infection.

Authors:  Angelica Papanicolaou; Hao Wang; Jonathan McQualter; Christian Aloe; Stavros Selemidis; Catherine Satzke; Ross Vlahos; Steven Bozinovski
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.